Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
650 participants
OBSERVATIONAL
2008-02-29
2010-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The main objective is to develop a tool which can be used for screening subjects at high risk for developing CKD (with hypertension and diabetes) as well as the general population.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prevalence of Chronic KIdney Disease in Hypertensive Patients
NCT00383968
A Primary-Secondary Care Partnership to Prevent Adverse Outcomes in Chronic Kidney Disease
NCT01688141
A Real World, Multi-centric, Observational Registry Study of Chronic Kidney Diseases
NCT05188885
Secondary Data Analysis of Patients at Risk for CKD to Inspect CKD Prevalence, Diagnosis Rates, Diagnostic Behaviour, Treatment Patterns and Patient Characteristics
NCT05953701
Improving Evidence-Based Primary Care for Chronic Kidney Disease
NCT01767883
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
A new GFR equation specific to a Pakistani population would be developed and validated using the gold standard of measured Insulin GFR. The performance of the new equation will be compared to the existing ones developed in other populations with respect to bias, precision, and accuracy.
The project is likely to contribute significantly to moving the field to kidney disease forward, and its results are likely to have far reaching implications for understanding of CKD and, ultimately, its prevention in Indo-Pakistani populations worldwide.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CROSS_SECTIONAL
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Acute fibril illness
* Doctor diagnosed liver disease
* Doctor diagnosed rheumatological disease
* Heart attack within past three months
* Pregnancy
* Mentally incompetent to give informed consent
* Too frail to travel to clinic
* Bed ridden subjects
40 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Aga Khan University
OTHER
National Institutes of Health (NIH)
NIH
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Aga Khan University
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Tazeen H Jafar, MD, MPH
Role: PRINCIPAL_INVESTIGATOR
Aga Khan University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Aga Khan University
Karachi, Sindh, Pakistan
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.